NO2198007T3 - - Google Patents

Info

Publication number
NO2198007T3
NO2198007T3 NO08830210A NO08830210A NO2198007T3 NO 2198007 T3 NO2198007 T3 NO 2198007T3 NO 08830210 A NO08830210 A NO 08830210A NO 08830210 A NO08830210 A NO 08830210A NO 2198007 T3 NO2198007 T3 NO 2198007T3
Authority
NO
Norway
Application number
NO08830210A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2198007T3 publication Critical patent/NO2198007T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
NO08830210A 2007-09-14 2008-09-15 NO2198007T3 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97249607P 2007-09-14 2007-09-14
PCT/US2008/010767 WO2009035707A1 (en) 2007-09-14 2008-09-15 Pharmaceutical compositions containing clostridium difficile toxoids a and b

Publications (1)

Publication Number Publication Date
NO2198007T3 true NO2198007T3 (cg-RX-API-DMAC7.html) 2018-03-24

Family

ID=40452372

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08830210A NO2198007T3 (cg-RX-API-DMAC7.html) 2007-09-14 2008-09-15

Country Status (21)

Country Link
US (3) US9320790B2 (cg-RX-API-DMAC7.html)
EP (3) EP4537849A3 (cg-RX-API-DMAC7.html)
JP (3) JP5503543B2 (cg-RX-API-DMAC7.html)
KR (2) KR101679812B1 (cg-RX-API-DMAC7.html)
CN (2) CN101855336B (cg-RX-API-DMAC7.html)
AU (1) AU2008299885C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0816790A8 (cg-RX-API-DMAC7.html)
CA (1) CA2699435A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119979T1 (cg-RX-API-DMAC7.html)
DK (1) DK2198007T3 (cg-RX-API-DMAC7.html)
ES (2) ES3001561T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180054T1 (cg-RX-API-DMAC7.html)
HU (1) HUE037932T2 (cg-RX-API-DMAC7.html)
IL (1) IL204366A (cg-RX-API-DMAC7.html)
MX (1) MX2010002815A (cg-RX-API-DMAC7.html)
NO (1) NO2198007T3 (cg-RX-API-DMAC7.html)
PL (1) PL2198007T3 (cg-RX-API-DMAC7.html)
PT (1) PT2198007T (cg-RX-API-DMAC7.html)
RU (1) RU2550271C2 (cg-RX-API-DMAC7.html)
SI (1) SI2198007T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009035707A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180054T1 (hr) 2007-09-14 2018-02-09 Sanofi Pasteur Biologics, Llc Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b
DK2753352T4 (da) 2010-09-03 2022-09-12 Valneva Austria Gmbh Isoleret polypeptid af toxin a og toxin b proteinerne fra c. difficile og anvendelser deraf
GB201105981D0 (en) * 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
ES2968629T3 (es) * 2011-04-22 2024-05-13 Wyeth Llc Composiciones relacionadas con una toxina mutante de Clostridium difficile y sus procedimientos
KR101135486B1 (ko) * 2011-05-25 2012-04-13 함종욱 보툴리눔 에이형 독소의 액상제품
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
KR102149206B1 (ko) 2012-11-08 2020-08-31 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 및 이의 용도
HRP20190711T1 (hr) 2012-12-05 2019-05-31 Glaxosmithkline Biologicals S.A. Imunogeni pripravak
CN111729077A (zh) 2013-03-14 2020-10-02 武田疫苗股份有限公司 减毒活甲病毒制剂的组合物和方法
CA2907156A1 (en) * 2013-03-15 2014-09-18 Sanofi Pasteur, Inc. Toxins, compositions and related methods
BR112015023332A2 (pt) * 2013-03-15 2017-08-22 Sanofi Pasteur Inc Toxóide, composições e método relacionados
EP3007724B1 (en) * 2013-06-14 2023-07-05 Sanofi Pasteur Inc. Compositions and methods of immunizing against c. difficile
BR112015031541A2 (pt) * 2013-06-17 2017-07-25 De Staat Der Nederlanden Vert Door De Mini Van Vws Miniie Van Volksgezondheid Welzijn En Sport métodos para o impedimento da agregação de componentes virais
US9930893B2 (en) * 2014-02-10 2018-04-03 The Johns Hopkins University Inhibitors of DXP synthase and methods of use thereof
UA122673C2 (uk) 2014-11-07 2020-12-28 Елевен Байотерапьютікс, Інк. Антитіло, що специфічно зв'язується з людським il-6
US20180110849A1 (en) 2015-05-15 2018-04-26 Sanofi Pasteur, Inc. Methods for immunizing against clostridium difficile
BE1023343B1 (nl) * 2015-05-20 2017-02-09 Mycartis Nv Opslagbuffer
KR20180116359A (ko) 2016-02-23 2018-10-24 세센 바이오, 아이엔씨. 인터루킨-6의 길항제 제제 및 이의 용도
PL3432916T3 (pl) 2016-09-13 2020-04-30 Allergan, Inc. Niebiałkowo stabilzowane kompozycje toksyny clostridium
ES2986389T3 (es) * 2018-05-21 2024-11-11 Chugai Pharmaceutical Co Ltd Formulación liofilizada sellada en un vial de vidrio
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879218A (en) * 1982-09-13 1989-11-07 Virginia Tech Intellectual Properties, Inc. Antibody for C.difficile
US5736139A (en) * 1989-10-31 1998-04-07 Ochidian Pharmaceuticals, Inc. Treatment of Clostridium difficile induced disease
JPH03193735A (ja) 1989-12-22 1991-08-23 Shionogi & Co Ltd グリコペプチド系抗生物質の安定化組成物
ES2104845T3 (es) * 1991-10-16 1997-10-16 Schering Corp Composiciones lipofilas de sales de antibioticos oligosacaridos.
AU4646393A (en) 1992-06-23 1994-01-24 Interactive Biologics Associates Pharmaceutical composition containing botulinum b complex
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
JPH08333277A (ja) 1995-06-05 1996-12-17 Hoechst Japan Ltd ヒト血液凝固第xiii因子の安定化された水性液製剤
CN1195993A (zh) * 1995-07-07 1998-10-14 奥拉瓦克斯有限公司 抗胃肠疾病的鼻内接种
US5932223A (en) 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
EP0892054B1 (en) * 1997-06-20 2006-11-29 Intervet International BV Clostridium perfringens vaccine
DE69829400T2 (de) * 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
EP1568378B1 (en) * 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
JP2000117967A (ja) * 1998-10-16 2000-04-25 Fuji Photo Film Co Ltd インクジェット記録方法
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DK1187629T3 (da) * 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6599715B1 (en) * 1999-05-12 2003-07-29 The Regents Of The University Of California Real time viability detection of bacterial spores
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
WO2003088946A1 (en) * 2002-04-19 2003-10-30 The Regents Of The University Of Michigan Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
DE10333317A1 (de) * 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
WO2005035573A1 (ja) 2003-10-09 2005-04-21 Chugai Seiyaku Kabushiki Kaisha タンパク質溶液の安定化方法
CN102139099A (zh) * 2004-07-26 2011-08-03 莫茨药物股份两合公司 包含肉毒杆菌神经毒素的治疗组合物
JP2008515996A (ja) * 2004-10-13 2008-05-15 イリプサ, インコーポレイテッド 毒素結合性オリゴ糖および重合体粒子を含有する医薬組成物
FR2881139A1 (fr) * 2005-01-26 2006-07-28 Agronomique Inst Nat Rech Composition pour la lyophilisation de proteines
US8137677B2 (en) 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
BRPI0613001B8 (pt) 2005-10-06 2021-05-25 Allergan Inc composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína
WO2007044809A2 (en) * 2005-10-11 2007-04-19 Botulinum Toxin Research Associates, Inc. Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use
EP2086581B1 (en) 2006-11-07 2014-08-13 Sanofi Pasteur Biologics, LLC Stabilization of vaccines by lyophilization
HRP20180054T1 (hr) 2007-09-14 2018-02-09 Sanofi Pasteur Biologics, Llc Farmaceutski pripravci koji sadrže toksoide clostridium difficile a i b
JP2012510497A (ja) * 2008-12-03 2012-05-10 ベーリンガー インゲルハイム フェトメディカ ゲゼルシャフト ミット ベシュレンクテル ハフツング ワクチンの生産方法

Also Published As

Publication number Publication date
IL204366A (en) 2013-02-28
US20110045025A1 (en) 2011-02-24
SI2198007T1 (en) 2018-04-30
WO2009035707A1 (en) 2009-03-19
EP2198007B1 (en) 2017-10-25
US9687541B2 (en) 2017-06-27
RU2010114730A (ru) 2011-10-20
ES3001561T3 (en) 2025-03-05
KR20160005378A (ko) 2016-01-14
JP2010539172A (ja) 2010-12-16
PT2198007T (pt) 2018-01-29
MX2010002815A (es) 2010-07-30
KR101679812B1 (ko) 2016-11-28
DK2198007T3 (en) 2018-01-15
WO2009035707A9 (en) 2010-06-10
EP2198007A1 (en) 2010-06-23
CN106039299A (zh) 2016-10-26
ES2657485T3 (es) 2018-03-05
US20160317640A1 (en) 2016-11-03
HRP20180054T1 (hr) 2018-02-09
KR20100075912A (ko) 2010-07-05
CA2699435A1 (en) 2009-03-19
EP4537849A2 (en) 2025-04-16
CY1119979T1 (el) 2018-12-12
EP2198007A4 (en) 2012-03-07
JP6258674B2 (ja) 2018-01-10
JP5503543B2 (ja) 2014-05-28
JP2014055174A (ja) 2014-03-27
CN101855336B (zh) 2019-07-30
BRPI0816790A8 (pt) 2017-05-16
EP3124044B1 (en) 2024-12-18
AU2008299885B2 (en) 2014-12-11
US20180000920A1 (en) 2018-01-04
EP3124044C0 (en) 2024-12-18
AU2008299885C1 (en) 2015-06-25
CN101855336A (zh) 2010-10-06
AU2008299885A1 (en) 2009-03-19
HUE037932T2 (hu) 2018-09-28
JP2017052773A (ja) 2017-03-16
EP4537849A3 (en) 2025-07-09
RU2550271C2 (ru) 2015-05-10
BRPI0816790A2 (pt) 2014-10-14
PL2198007T3 (pl) 2018-03-30
EP3124044A1 (en) 2017-02-01
US9320790B2 (en) 2016-04-26
US10639362B2 (en) 2020-05-05
EP3124044B8 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
CN300729872S (zh) 金属轮毂(405)
CN300731361S (zh) 外包装纸(老临沧茶叶)
CN300726571S (zh) 被子
CN300726661S (zh) 锅(4)
CN300726841S (zh) 包装瓶(营养素2号)
CN300726848S (zh)
CN300727349S (zh) 自行车车架管(hh-t13-5048)
CN300732336S (zh) 称重显示仪(tad7)
CN300728088S (zh) 玩具机器人(28108a)
CN300730024S (zh) 电脑音箱(h2602)
CN300731420S (zh) 摇椅(13)
CN300727351S (zh) 摩托车(426)
CN300727398S (zh) 汽车后保险杠
CN300727524S (zh) 电连接器
CN300727849S (zh) 橡皮(k-0714)
CN300731592S (zh) 书柜(w802五门)
CN300728389S (zh) 电石照明灯
CN300728502S (zh) 冰淇淋机
CN300728859S (zh) 沙发(1081)
CN300728883S (zh) 转椅(13)
CN300729153S (zh) 汤锅(zc系列)
CN300729216S (zh) 广告用食品罩(四方形)
CN300729321S (zh) 滑轮(一)
CN300729335S (zh) 手柄(zc系列)
CN300731853S (zh) 箱包拉杆手把(2)